Corbus Pharmaceuticals In (CRBP) Stock
Small biopharma developing treatments for inflammatory diseases. Here's the price, business snapshot, and what's worth knowing about Corbus Pharmaceuticals In in June 2026.
Corbus Pharmaceuticals (CRBP) is a small-cap, clinical-stage biopharmaceutical company developing therapies targeting inflammatory and fibrotic diseases. The company’s valuation is driven largely by progress in its clinical programmes, regulatory readouts and partnerships rather than product sales. With a market capitalisation around $237 million, Corbus is typical of clinical-stage names: potential for significant upside if trials succeed, but also considerable downside risk if studies or approvals disappoint. Investors should watch trial milestones, cash runway and financing activity closely, as companies at this stage often require additional capital, which can dilute shareholders. There is limited or no meaningful recurring revenue, so the business depends on successful development, licensing deals and disciplined cash management. This summary is educational, not personal advice; values can rise and fall and past performance does not guarantee future results. Consider your risk tolerance and consult a financial professional for tailored guidance.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Corbus Pharmaceuticals stock with a target price of $69.6, indicating significant growth potential.
Financial Health
Corbus Pharmaceuticals is showing strong financial performance with solid cash flow and book value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring CRBP
Oral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketObesity Drug Stocks: Medicare Coverage Trade-offs
A new agreement between the Trump administration, Eli Lilly, and Novo Nordisk will dramatically lower the cost of GLP-1 weight loss drugs and expand Medicare coverage. This move is expected to significantly increase patient access and boost sales, creating opportunities for the drug manufacturers and their key suppliers.
Published: 7 November 2025
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketOzempic Price Pressure | Pharma Investment Shift
A recent announcement of plans to slash prices for major weight-loss drugs has created turmoil for market leaders Novo Nordisk and Eli Lilly. This theme explores the investment opportunities that arise for competing pharmaceutical companies and developers of alternative treatments who may benefit from this market disruption.
Published: 21 October 2025
Explore BasketWeight-Loss Drug Shakeup: What's Next for Biotechs?
Following former President Trump's pledge to slash prices for popular weight-loss drugs, uncertainty has hit major pharmaceutical stocks. This theme identifies competitor firms and biotechs that could gain an edge as the pricing landscape for metabolic drugs shifts.
Published: 18 October 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Progress in late-stage trials or regulatory readouts can move the share price materially, though trial outcomes are uncertain and can swing value both ways.
Funding & Dilution Risk
Small-cap clinical firms often need fresh capital; watch cash runway and financing plans because new funding can dilute existing holders.
Market Opportunity Focus
If approved, therapies for inflammatory and fibrotic diseases can address sizeable unmet needs, but commercial success depends on reimbursement and competition.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
